LB Pharmaceuticals Names Joseph Miller CFO

LB PHARMACEUTICALS INC (LBRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update Strengthened leadership with the appointment of Susan G. Kozauer, M.D., as Chief Medical Officer and Joseph Miller as Chief Financial Officer On track for topline data reado

LB Pharmaceuticals reported Q3 2026 results, appointing new CFO and CMO. The company expects topline data from its Phase 3 NOVA-2 trial of LB-102 in schizophrenia in 1H 2027. It raised $150M in a private placement and has $403.8M in cash, expected to fund operations beyond Q2 2029. LB-102 is in late-stage development for schizophrenia, bipolar depression, and MDD.

Guggenheim reiterated a Buy rating and $80.00 price target on LB Pharmaceuticals (LBRX) after new preclinical study results for LB-102. The stock has risen 141% in the past year to $37.22. The company has more cash than debt. Analysts estimate U.S. peak sales of $2.1B for schizophrenia and $1.3B for bipolar depression. Other analysts also raised price targets and ratings.

LB Pharmaceuticals (LBRX) presented preclinical and clinical data on LB-102 at the ECNP congress. The data showed LB-102's potential to modulate dopamine signaling and improve cognitive performance in schizophrenia. The company also detailed ongoing Phase 3 trials for schizophrenia and a Phase 2 trial for bipolar depression.

LB Pharmaceuticals (LBRX) presented preclinical data at the ECNP Congress, showing LB-102 increased dopamine signaling in rats, potentially addressing low motivation in depression. The company is developing LB-102 for schizophrenia and bipolar depression, with ongoing Phase 3 and Phase 2 trials.

LB Pharmaceuticals (LBRX) reported Q2 2026 results and updated its LB-102 schizophrenia program. The company expects earlier topline Phase 3 NOVA-2 data in 1H 2027 and a pre-NDA FDA meeting in 2H 2027. It is also advancing bipolar I depression (Q1 2028) and planning adjunctive MDD (1H 2029). R&D was $44.1M, net loss $51.6M, and it raised $150M.